Drugs / B244
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03775434 | Dec 2018 → May 2019 | atopic eczema | AOBiome LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02656485 | Aug 2015 → Mar 2016 | acne | AOBiome LLC | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT04490109 | Jun 2020 → Dec 2021 | atopic eczema | AOBiome LLC | Completed | Met primary |
| Phase 2 | NCT03488563 | Mar 2018 → Jun 2019 | migraine disorder | AOBiome LLC | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 1/2 | NCT03290248 Comparator | Sep 2017 → Dec 2018 | seasonal allergic rhinitis | AOBiome LLC | Completed | No outcome recorded |
| Phase 2 | NCT03590366 Comparator | Jul 2018 → Feb 2019 | rosacea | AOBiome LLC | Completed | No outcome recorded |
| Phase 2 | NCT03235024 Comparator | Jan 2018 → Feb 2019 | atopic eczema | AOBiome LLC | Completed | No outcome recorded |
| Phase 2 | NCT02998840 Comparator | Nov 2016 → Apr 2017 | hypertensive urgency | AOBiome LLC | Completed | No outcome recorded |
| Phase 2/3 | NCT02832063 Comparator | Aug 2016 → Jul 2017 | acne | AOBiome LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
All press releases naming this drug 11 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B244 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03488563 ↗ |
| Modality | Other / unclassified | “B244 is a live topical biotherapeutic being tested for the reduction of pruritus and improvement of eczema signs in patients with AD.” PMID 37396805 ↗ May 2023 |
| Route | Topical | “B244 Delivered as a Topical Spray” NCT02656485 ↗ |